Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Withdraws Psoriasis Drug Application

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott Laboratories is withdrawing its U.S. and European applications for experimental psoriasis drug briakinumab, citing regulators request for more research.

You may also be interested in...



Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into

The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.

Abbott Shaves U.S. Pharma Costs With Restructuring

Abbott plans to eliminate 1,900 positions, mainly within commercial and manufacturing, in a restructuring that will yield pre-tax savings of $200 million.

Abbott Shaves U.S. Pharma Costs With Restructuring

Abbott plans to eliminate 1,900 positions, mainly within commercial and manufacturing, in a restructuring that will yield pre-tax savings of $200 million.

Topics

UsernamePublicRestriction

Register

PS071694

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel